October 22, 2024 03:38 PM EDT

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

Zachary Brennan

Senior Editor

Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron’s blockbuster Eylea, following an appeals court decision that ruled against competitor Regeneron …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Updated: Pfizer's activist says board must 'hold management accountable' for R&D shortcomings

Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Ahead of Novo’s CagriSema readout, Lilly returns to a promising new class of obesity drugs

Be Bio raises $82M to fund work on B cell therapy in hemophilia B

Roche, Genentech end anti-tau Alzheimer’s drug collaboration with UCB

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Am­gen preps to launch Eylea biosim­i­lar years ear­ly af­ter Re­gen­eron los­es ap­peal

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Up­dat­ed: Pfiz­er's ac­tivist says board must 'hold man­age­ment ac­count­able' for R&D short­com­ings

Sang­amo to seek ac­cel­er­at­ed ap­proval for Fab­ry gene ther­a­py, claims it won't need con­fir­ma­to­ry study

Ahead of No­vo’s Ca­griSe­ma read­out, Lil­ly re­turns to a promis­ing new class of obe­si­ty drugs

Be Bio rais­es $82M to fund work on B cell ther­a­py in he­mo­phil­ia B

Roche, Genen­tech end an­ti-tau Alzheimer’s drug col­lab­o­ra­tion with UCB

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal

Updated: Pfizer's activist says board must 'hold management accountable' for R&D shortcomings

Sangamo to seek accelerated approval for Fabry gene therapy, claims it won't need confirmatory study

Ahead of Novo’s CagriSema readout, Lilly returns to a promising new class of obesity drugs

Be Bio raises $82M to fund work on B cell therapy in hemophilia B

Roche, Genentech end anti-tau Alzheimer’s drug collaboration with UCB

IDEAYA Biosciences: Targeting unmet market needs with precision oncology